Predict your next investment

HEALTHCARE | Medical Devices & Equipment
delcath.com

See what CB Insights has to offer

Founded Year

1988

Stage

PIPE - III | IPO

Total Raised

$1.39M

Market Cap

0.05B

Stock Price

6.61

About Delcath Systems

Delcath has developed a system to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver. Using the Delcath system to deliver chemotherapy to the liver and cleanse the blood of the chemotherapy before its return from the liver into the patient's circulatory system protects other parts of the body from the harmful side-effects of chemotherapy. The Company believes that the use of the Delcath system in treatment of liver cancer will allow higher dosages of chemotherapy to be administered to the liver than can be administered with conventional intravenous delivery.

Delcath Systems Headquarter Location

600 Fifth Avenue 23rd Floor

New York, New York, 10020,

United States

212-489-2100

Latest Delcath Systems News

Delcath Systems To Present At The H.C. Wainwright BioConnect Virtual Investor Conference On January 10, 2022

Jan 7, 2022

Delcath Systems To Present At The H.C. Wainwright BioConnect Virtual Investor Conference On January 10, 2022 NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. Author: Jan 7, 2022 9:00 AM EST NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:  DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference: H.C. Wainwright BioConnect Virtual Investor Conference January 10-13, 2022 Presentation Date and Time: On-demand beginning January 10, 2022 at 7:00 AM (ET) Management will also host 1x1 investor meetings during the conference. To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or james@haydenir.com. About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA). In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Delcath Systems Patents

Delcath Systems has filed 12 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Oncology
  • Cancer treatments
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/22/2018

8/10/2021

Pharmacokinetics, Filters, Brown dwarfs, Medical equipment, Immunology

Grant

Application Date

12/22/2018

Grant Date

8/10/2021

Title

Related Topics

Pharmacokinetics, Filters, Brown dwarfs, Medical equipment, Immunology

Status

Grant

Delcath Systems Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Delcath Systems Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.